ML22308A050

From kanterella
Jump to navigation Jump to search
Presentation 2 Chapman NRC Background Slides Nov 3 2022 Discrete Radioactive Particle (DRP) Workshop
ML22308A050
Person / Time
Issue date: 11/03/2022
From: Gregory Chapman
Office of Nuclear Material Safety and Safeguards
To:
References
Download: ML22308A050 (15)


Text

Discrete Radioactive Particle (DRP)

Considerations in Decommissioning Greg Chapman Senior Health Physicist DRP Public Workshop November 3, 2022

What is a DRP?

Discrete Radioactive Particle = Hot Particle Per IN 90-48, NCRP 106, etc.

Examples of DRPs

- Neutron activated metal (legacy wearing particles, cuttings from reactor vessel (RV)/RV internals/rebar in bioshield, etc.)

- Legacy fuel flea (spent fuel)

- Neutron activated bioshield concrete (primarily Europium (Eu) isotopes)

- Others (e.g., natural Thorium from welding/cutting, damaged sources, etc.)

What are the issues?

  • Understanding contamination events and risk of DRPs being released to the environment
  • Ability to scan for/identify DRPs in soil
  • Potential exposures to average member of the critical group (exposure scenarios?)

What can be left behind? What is the risk of that material? What is acceptable?

Current Regulatory Requirements

  • Decommissioning/Unrestricted Release Requirement:

25 mrem/y Total Effective Dose Equivalent (TEDE)

  • Public Dose Limit: 100 mrem/y TEDE
  • No deterministic effect limits for public in 10 CFR 20
  • Deterministic Effect Limits:

- 15 rem/y to lens of eye

- 50 rem/10 cm2 shallow dose equivalent (SDE) for skin

- 50 rem/y Committed Dose Equivalent (CDE) to organ

  • Basis: ICRP 26/30
  • SDE/local DE is not a contributor to TEDE so it can be problematic

- area averaging could be 1 cm2 or 10 cm2 for skin, 1 cm2 for internal organs

Previous Regulatory Evaluations

- 50 rem over 10 cm2 the worst-case deterministic effects are a 5-percent probability of erythema if all of the dose (500 rem) were delivered to an area of 2.5 square centimeters, and a 50-percent probability that measurable dermal thinning would be observable if all of the dose were delivered to an area of <0.5 square centimeters. At this dose, no acute cell killing or skin ulceration was predicted for DRPs 3 or more millimeters off the skin because the dose is distributed over too large an area. The worst case probability of producing a barely detectable scab as a result of acute cell killing was estimated to be 10 percent for 60Co or activated fuel DRPs located about 0.4 mm off the skin. Additional discussion of implications of the health effects associated with the proposed unified skin dose limit can be found in the regulatory analysis developed for this rulemaking.

Aerodynamic Diameter AMAD AMAD: Activity Median Aerodynamic Diameter 10 m generally considered largest respirable particle size (aerodynamic equivalent not AMAD).

Size matters, volume/radioactivity increase by power of 3 as size increases

ICRP 26/30 Biokinetic Models not Ideal for Assessing Dose from DRPs Lung Model

Alimentary Tract Model Potential Public DRP Exposures Outside of 10 CFR 20?

  • Skin dose (SDE using VARSKIN)
  • Ingestion/Inhalation of an insoluble particle

- local" DE dose to respiratory and alimentary track lining (using VARSKIN [SDE])

Research Assistance

  • Renaissance Code Development (RCD)- Developing a particle appropriate inhalation/ingestion localized DE/EDE/CDE Dose Conversion Factors (DCFs) and skin SDE/EDE DCFs for most significant radioisotopes

- To make it relatively easy to estimate potential exposures to DRPs

  • ORISE - Developing methodology/examples for determining a scan minimum detectable activity (MDA) similiar to MARSSIM methods

- Expected to potentially have multiple applications (e.g.,

discrete source materials)

  • Draft reports are being made publicly available

General Considerations for DRPs

  • DRP management should be continued from operations through decommissioning
  • DRPs generated through decommissioning activities should be controlled at the source
  • If a release to environment occurs, licensees should take corrective action to identify the extent of release, remediate as appropriate, and document surveys to support potential license termination reviews

- The quicker the better to avoid secondary environmental transport

  • If DRPs are anticipated to be present in the environment, it should be discussed in the license termination plan (LTP) or decommissioning plan (DP)

Decommissioning DRP Experience

  • Yankee Rowe
  • Rancho Seco
  • Shelwell*

NRC efforts to address DRPs

  • Developing methods and/or guidance for

- Acceptable dosimetry methods for DRPs

- Scanning for detection of DRPs

  • Potential Generic Communications in 2023

- Preventing/documenting release of DRPs during decommissioning

Questions